Literature DB >> 18319306

Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche.

Lourdes Ibáñez1, Abel López-Bermejo, Marta Díaz, Maria Victoria Marcos, Francis de Zegher.   

Abstract

CONTEXT AND
OBJECTIVE: A low birth weight (LBW) tends to be followed by overweight due to an excess of fat, including visceral fat. LBW girls with precocious pubarche (PP) (pubic hair < 8 yr) are at high risk for developing an adipose state of hyperinsulinemic androgen excess that leads toward early menarche. We explored the effects of insulin sensitization with metformin in LBW-PP girls. SETTING, DESIGN, PATIENTS, INTERVENTION: Prepubertal LBW girls with PP (mean body weight 2.4 kg; age 7.9 yr; body mass index 18.4 kg/m(2)) were studied. Girls were randomly assigned to remain untreated (n=19) or receive metformin for 4 yr (n = 19; 425 mg/d for 2 yr, then 850 mg/d for 2 yr). MAIN OUTCOMES: At the start and after 4 yr, height, weight, fasting insulin, glucose, IGF-I, testosterone, lipids, leptin, high molecular weight adiponectin, body composition by absorptiometry, abdominal fat partitioning (only 4 yr) by magnetic resonance imaging, and menarcheal status were determined.
RESULTS: Metformin-treated girls gained on average 5.5 kg (or approximately 50%) less fat, after 4 yr were less insulin resistant and less hyperandrogenic, had lower IGF-I levels and a less atherogenic lipid profile, and were less likely to be post-menarcheal than untreated girls, whereas their gain in height, lean mass, and bone mineral density were similar. After 4 yr, untreated girls had more visceral fat, a higher ratio of visceral-to-sc fat, and a higher leptin-to-high molecular weight adiponectin ratio (all approximately 50% higher) than metformin-treated girls.
CONCLUSION: Long-term metformin treatment appears to reduce total and visceral fat in LBW-PP girls, and to delay menarche without attenuating linear growth, thereby opening the perspective that adult height may be increased.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319306     DOI: 10.1210/jc.2008-0013

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Perspectives in Polycystic Ovary Syndrome: From Hair to Eternity.

Authors:  Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

2.  Approach to the girl with early onset of pubic hair.

Authors:  Sharon E Oberfield; Aviva B Sopher; Adrienne T Gerken
Journal:  J Clin Endocrinol Metab       Date:  2011-06       Impact factor: 5.958

3.  The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.

Authors:  Gwinnett Ladson; William C Dodson; Stephanie D Sweet; Anthony E Archibong; Allen R Kunselman; Laurence M Demers; Nancy I Williams; Ponjola Coney; Richard S Legro
Journal:  Fertil Steril       Date:  2010-12-30       Impact factor: 7.329

Review 4.  Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.

Authors:  Mehrul Hasnain; W Victor R Vieweg; Sonja K Fredrickson
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

5.  Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial.

Authors:  Jack A Yanovski; Jonathan Krakoff; Christine G Salaita; Jennifer R McDuffie; Merel Kozlosky; Nancy G Sebring; James C Reynolds; Sheila M Brady; Karim A Calis
Journal:  Diabetes       Date:  2011-01-12       Impact factor: 9.461

6.  A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess.

Authors:  Abel López-Bermejo; Marta Díaz; Erica Morán; Francis de Zegher; Lourdes Ibáñez
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 19.112

Review 7.  Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism.

Authors:  Lourdes Ibáñez; Rubén Díaz; Abel López-Bermejo; Maria Victoria Marcos
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

Review 8.  Polycystic Ovary Syndrome: Ontogeny in Adolescence.

Authors:  Christine M Burt Solorzano; Christopher R McCartney
Journal:  Endocrinol Metab Clin North Am       Date:  2021-01-11       Impact factor: 4.741

Review 9.  New Horizons in Short Children Born Small for Gestational Age.

Authors:  Irène Netchine; Manouk van der Steen; Abel López-Bermejo; Ekaterina Koledova; Mohamad Maghnie
Journal:  Front Pediatr       Date:  2021-05-13       Impact factor: 3.418

10.  Hyperinsulinaemic androgen excess in adolescent girls.

Authors:  Lourdes Ibáñez; Ken K Ong; Abel López-Bermejo; David B Dunger; Francis de Zegher
Journal:  Nat Rev Endocrinol       Date:  2014-04-29       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.